Loading…
Pharmaceuticals · NSE · period ending 2026-03-31
Loading chart…
✓ Core business is permissible and non-compliant income is 4.74% of revenue (limit 5%).
| Ratio | Value | Limit | Result |
|---|---|---|---|
| Interest-bearing debt / market cap | 0% | < 30% | Pass |
| Interest-bearing investments / market cap | 6.58% | < 30% | Pass |
The underlying figures and the filing citations they came from are available with a free account.
Sign up free4.74% of any dividend from CAPLIPOINT should be given to charity. Calculate your amount →
Very strong gains across 1–6 months and trading at its 52‑week high signal a powerful uptrend, even though 50DMA has not yet crossed above 200DMA. High volatility underscores the strength and speed of the move.
Computed from delayed price history and desk sentiment. Educational context only — not investment advice or a price prediction.
Compliance watch: verdict re-verified against live market cap on 13 Jun 2026 · rechecked every 6 hours · filings reviewed quarterly.